Startup Funding News
Explore funding rounds, the companies behind them and the investors taking part.
- Rounds
- 473 All time
- Disclosed funding
- $19.6B 400 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| AO Atlas Oncology PartnersCompany profile Delivers uplifting and responsive cancer care during and beyond treatment Delivers uplifting and responsive cancer care during and beyond treatment | $28M | Series A | Biotech, Healthtech | United States | Investors | |
| 4B 4Moving BiotechCompany profile Clinical-stage development of a locally delivered GLP-1 therapy for inflammatory knee osteoarthritis. Clinical-stage development of a locally delivered GLP-1 therapy for inflammatory knee osteoarthritis. | €12M | Debt and equity financingUndisclosed | Biotech | France | Investors Undisclosed | |
| A ArrayPatchCompany profile Develops microneedle-based therapeutics for treatment of nail fungus and other diseases Develops microneedle-based therapeutics for treatment of nail fungus and other diseases | €3M | Seed | Biotech, Healthtech | Ireland | Investors | |
| IB Developing a next-generation pertussis vaccine candidate BPZE1 | $115M | Series B | Biotech | United States | Investors | |
| PT Pandorum TechnologiesCompany profile Develops tunable, regenerative exosome therapies for tissue health, disease, and degeneration Develops tunable, regenerative exosome therapies for tissue health, disease, and degeneration | $18M | Series B | Biotech | India | Investors | |
| G GaluxCompany profile Develops AI-driven protein design platform for de novo antibody and drug discovery Develops AI-driven protein design platform for de novo antibody and drug discovery | $29M | Series B | Biotech | South Korea | Investors | |
| TA Third Arc BioCompany profile Develops novel multifunctional antibodies for oncology and immunology & inflammation indications Develops novel multifunctional antibodies for oncology and immunology & inflammation indications | $52M | Series A+Series A | Biotech | United States | Investors | |
| ES Evergreen SelectCompany profile Produces cultivated beef for integration into existing food-production systems. Produces cultivated beef for integration into existing food-production systems. | $6M | Undisclosed | Biotech, Foodtech | United States | Investors | |
| QS Develops quantum-based platform for real-time cell analysis | €4M | Seed | Biotech | Netherlands | Investors | |
| b Physician-led preventive care platform using AI for early cancer detection | $4M | Seed | Biotech, Healthtech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.
Browse rounds by topic
Geography
Featured selections
Nordic Foodtech Fund II pairs early capital with scientific expertise
An EIF pledge of up to €30m supports a fund targeting €80m for science-led agrifood companies.
Read the research →